Onconetix Past Earnings Performance
Past criteria checks 0/6
Onconetix's earnings have been declining at an average annual rate of -66.3%, while the Biotechs industry saw earnings growing at 16.9% annually.
Key information
-66.3%
Earnings growth rate
-20.5%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -178.5% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Onconetix makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -18 | 11 | 3 |
| 30 Jun 23 | 0 | -17 | 9 | 4 |
| 31 Mar 23 | 0 | -14 | 10 | 5 |
| 31 Dec 22 | 0 | -14 | 9 | 4 |
| 30 Sep 22 | 0 | -12 | 8 | 3 |
| 30 Jun 22 | 0 | -9 | 6 | 2 |
| 31 Mar 22 | 0 | -6 | 3 | 2 |
| 31 Dec 21 | 0 | -4 | 2 | 1 |
| 30 Sep 21 | 0 | -3 | 2 | 1 |
| 30 Jun 21 | 0 | -2 | 1 | 1 |
| 31 Mar 21 | 0 | -2 | 1 | 0 |
| 31 Dec 20 | 0 | -2 | 1 | 1 |
Quality Earnings: J4T is currently unprofitable.
Growing Profit Margin: J4T is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: J4T is unprofitable, and losses have increased over the past 5 years at a rate of 66.3% per year.
Accelerating Growth: Unable to compare J4T's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: J4T is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: J4T has a negative Return on Equity (-178.55%), as it is currently unprofitable.